# Inhaled immune therapy to make the lung hostile to arriving tumour cells

Source: https://onco.cc/ideas/idea-bio2-inhaled-lung-niche-immunotherapy/  
OnCo record `idea-bio2-inhaled-lung-niche-immunotherapy` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Breathing in an immune-activating drug could turn the lungs into bad soil for cancer seeds, at doses far too low to cause body-wide side-effects.

## Summary

Inhaled GM-CSF was tested in paediatric osteosarcoma lung metastases and inhaled interleukin-2 in renal cancer, both with local immune activation, acceptable safety and underpowered efficacy. Modern versions (an inhaled interleukin-15 superagonist, an inhaled STING agonist or an inhaled anti-CD47) could be aimed at lung-metastasis prevention rather than treatment, where the target cell burden is tiny.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: Inhaled alveolar immune activation after resection of a lung-tropic tumour halves lung-specific relapse without systemic cytokine toxicity.
- Rationale: Metastasis prevention needs high local and low systemic exposure, and the lung is the only metastatic site with a direct non-invasive delivery route. Alveolar macrophage reprogramming is the mechanistic target and is measurable by bronchoalveolar lavage.
- Proposed test: A phase 1/2 in resected osteosarcoma or lung-tropic sarcoma with lavage-based pharmacodynamics, then a randomised trial with lung-relapse-free survival as the primary endpoint.
- Maturity: preclinical-evidence
- Actor: research

## Sources

- Bottleneck evidence (Metastasis is understood least and studied last): Dillekås et al., Are 90% of deaths from cancer caused by metastases? (Cancer Medicine 2019): https://doi.org/10.1002/cam4.2474

## Connected records

- cancers: [Renal cell carcinoma](https://onco.cc/cancers/rcc/), [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)
- technologies: [Cytokines & engineered cytokines](https://onco.cc/technologies/cytokine-therapy/), [STING & innate immune agonists](https://onco.cc/technologies/sting-agonist/)
- targets: [CD47](https://onco.cc/targets/cd47/)
- companies: [Children's Oncology Group (COG)](https://onco.cc/companies/childrens-oncology-group/)
- bottlenecks: [Cold tumours and the immunosuppressive microenvironment](https://onco.cc/bottlenecks/b-tme-immunosuppression/), [Metastasis is understood least and studied last](https://onco.cc/bottlenecks/b-metastasis-biology/)
- key papers: [Are 90% of deaths from cancer caused by metastases?](https://onco.cc/key-papers/paper-dillekas-cancer-med/)

---
JSON: https://onco.cc/api/v1/entities/idea-bio2-inhaled-lung-niche-immunotherapy.json